Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

NCT06119685 is registered in ClinicalTrials.gov with Indapta Therapeutics, INC. as lead sponsor.

NCT NCT06119685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06119685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Lead sponsor
Indapta Therapeutics, INC.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 25, 2023
Completion date
December 31, 2029
Enrollment
128 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

blood cancer, multiple myeloma, nhl, refractory multiple myeloma, refractory non-hodgkin lymphoma, relapsed multiple myeloma, relapsed non-hodgkin lymphoma